NCT03829579Approved For Marketing不适用
Esketamine Single Patient Request
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have exhausted all other treatment options, including all alternative treatment options with marketed therapies.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have an unmet medical need to treat treatment-resistant depression (TRD) with esketamine nasal spray, an investigational compound, that has not been approved by any health authority. This means no other treatment options are available and the participant must be unable to participate in a clinical trial; for example, because they do not fulfill the eligibility criteria of the protocol or there are no trial sites within a reasonable distance of where they reside
- •Must not participate in a clinical trial or be concurrently treated with an investigational drug when being treated with esketamine nasal spray
- •Participants must have TRD with the diagnosis verified by a psychiatrist, and have exhausted all other options including all alternative treatment options with marketed therapies, specifically:
- •Participant must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnostic criteria for single-episode major depressive episode (major depressive disorder [MDD]) (if single-episode MDD, the duration must be greater than [>]2 years) or recurrent MDD, without psychotic features.
- •Participant must have had nonresponse to 2 or more oral antidepressant treatments in the current episode of depression confirmed by documented medical history and/or pharmacy/prescription records to meet criteria for TRD and have failed at least one augmentation strategy (for example, atypical antipsychotics such as aripiprazole or quetiapine, lithium, thyroid hormones, bupropion, etc) and have failed an adequate course (greater than or equal to [>=] 7 unilateral [UL] sessions) of, or have a contraindication to electro-convulsive therapy (ECT) and transcranial magnetic stimulation (TMS)
- •Participants must have exhausted clinical trials, early access programs or named patient programs that may be available in their region
- •Participants must have moderate to severe depression per clinical judgment
排除标准
- •The participant's depressive symptoms have previously demonstrated nonresponse to Esketamine Nasal Spray or ketamine in the current major depressive episode per clinical judgment
- •Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychosis, bipolar or related disorders, comorbid obsessive- compulsive disorder, intellectual disability (only DSM-5 diagnostic code 319), borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
- •Participant has homicidal ideation/intent or has suicidal ideation with some intent to act within 6 months or a history of suicidal behavior within the past year, per the requesting psychiatrist's clinical judgment
- •Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of the first dose.
- •a) A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
- •Participants with a current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
研究者
相似试验
Unknown
不适用
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05503550Janssen Research & Development, LLC
Unknown
不适用
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05757973Janssen Research & Development, LLC
No Longer Available
不适用
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Multiple MyelomaNCT05238311Pfizer
Available
不适用
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.Colitis, UlcerativeNCT06025227Pfizer
Approved For Marketing
不适用
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) DaratumumabNCT04264884Janssen Research & Development, LLC